This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Munshi, A. Articles by Meyn, R. E. Search for Related Content PubMed PubMed Citation Articles by Munshi, A. Articles by Meyn, R. E.

Departments of ¹ Experimental Radiation Oncology, ² Surgical Oncology, and ³ Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Raymond E. Meyn, Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Box 066, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-3424; Fax: 713-794-5369. E-mail: rmeyn{at}mdanderson.org

Melanoma tumors and cultured cell lines are relatively resistant to the cytotoxic effects of ionizing radiation, thereby limiting the use of radiotherapy for the clinical treatment of melanoma. New strategies for sensitizing melanoma cells therefore deserve examination. In an attempt to identify and target signaling pathways that contribute to radioresistance, we investigated the role of nuclear factor-B (NF-B), a transcription factor known to inhibit apoptosis induced by a variety of stimuli and promote radioresistance. Two human metastatic melanoma cell lines, A375 and MeWo, were used to examine the radiosensitizing effects of inhibitors of the NF-B pathway. Nuclear extracts from these cell lines were tested for active NF-B using the electrophoretic mobility shift assay. Both melanoma cell lines had constitutively activated NF-B as observed by electrophoretic mobility shift assay. In an attempt to reverse NF-B activity, cells were treated either with vehicle alone (DMSO) or with a proteasome inhibitor Z-Leu-Leu-Leu-H (MG132; 10 µmol/L for 2 hours prior to irradiation) that inhibited both constitutive and radiation-induced NF-B activity. The clonogenic cell survival assay showed that pretreatment with MG132 enhanced tumor cell radiosensitivity with the survival factor at 2 Gy being reduced from 48 ± 0.8% and 48 ± 1.6% in vehicle-treated cells to 27.7 ± 0.32% and 34.3 ± 0.7% in MG132-treated MeWo and A375 cells, respectively. To test the role of NF-B in radioresistance more directly, MeWo cells were stably transfected with a dominant-negative mutant IB construct, which led to the inhibition of both constitutive and radiation-induced NF-B activity. A modest restoration of radiosensitivity was also observed in the stably transfected MeWo cells with survival factor at 2 Gy values being reduced from 47 ± 0.8% in parental MeWo cells to 32.9 ± 0.7% in stable transfectants. Because constitutively activated mitogen-activated protein kinase kinase (MEK) pathway has been shown to lead to activated NF-B, we wanted to determine the relative contribution of activated MEK in the human melanoma cells. To test this, MeWo and A375 melanoma cells were exposed to the MEK inhibitor PD184352. Treatment with PD184352 partially reversed NF-B activity but did not impart radiation sensitivity to these cells. Our results indicate that activated NF-B may be one of the pathways responsible for the radioresistance of melanoma cells and that strategies for inhibiting its influence may be useful in restoring the radioresponse of melanomas.

Note: A. Munshi and J.F. Kurland contributed equally to this work. J.F. Kurland is currently at Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 7/24/03; revised 5/12/04; accepted 5/14/04.